Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.33 |
| ▸ | MIF | P14174 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 4/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | TYR | P14679 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1860093 | 0.87 | PKM (0.38) | SMN1; SMN2PKMTSHRKMT2A | |
| SCHEMBL1860700 | 0.86 | AKR1B1 (0.33) | GRM5MIFMAPTSMN1; SMN2TYR | |
| SCHEMBL12489682 | 0.85 | KDM4E (0.39) | MAPTSMN1; SMN2TYRPKMTSHR | |
| SCHEMBL981067 | 0.84 | MAPT (0.34) | GRM5MIFMAPTSMN1; SMN2TYR | |
| SCHEMBL981094 | 0.82 | GRM5 (0.33) | GRM5MIFMAPTALDH1A1RECQL | |
| SCHEMBL1305787 | 0.82 | CA1 (0.30) | — | |
| SCHEMBL3757273 | 0.81 | GRM5 (0.33) | GRM5MAPTSMN1; SMN2TYRALDH1A1 | |
| SCHEMBL3110379 | 0.81 | — | — | |
| SCHEMBL3105354 | 0.81 | RECQL (0.30) | RECQL | |
| SCHEMBL3649341 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044075-B1 | FURO [3, 2-B] PYRROL DERIVATIVES | AMURA THERAPEUTICS LTD (GB) | 2013-01-02 | — | — | EP | disclosed |
| EP-2046796-B1 | TETRAHYDROFURO [3, 2 -B]PYRR0L-3-ONES AS CATHEPSIN K INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2012-10-24 | — | — | EP | disclosed |
| US-8053452-B2 | Substituted isoxazoline or enone oxime compound, and pest control agent | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-11-08 | — | — | US | disclosed |
| US-8053437-B2 | Furo[3. 2-B] pyrrol derivatives | AMURA THERAPEUTICS LIMITED (GB) | 2011-11-08 | — | — | US | disclosed |
| US-20100216811-A1 | FURO[3. 2-B] PYRROL DERIVATIVES | AMURA THERAPEUTICS LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| US-20100144808-A1 | SUBSTITUTED ISOXAZOLINE OR ENONE OXIME COMPOUND, AND PEST CONTROL AGENT | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-06-10 | — | — | US | disclosed |
| EP-2172448-A1 | SUBSTITUTED ISOXAZOLINE OR ENONE OXIME COMPOUND, AND PEST CONTROL AGENT | Nissan Chemical Industries, Ltd. (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-20090186906-A1 | N-((S)-4,4-dimethyl-1-oxo-1-((3aS,6aR)-3-oxo-dihydro-2H-furo[3,2-b]pyrrol-4(5H6H, 6aH)-yl)pentan-2-yl)-4-(4-methylpiperazin-1-yl)benzamide; treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, bone cancer | AMURA THERAPEUTICS LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216811-A1 | FURO[3. 2-B] PYRROL DERIVATIVES | THPO, COL2A1, COL1A1 | GRM5 1535/4885MIF 393/4885MAPT 336/4885 |
| US-20090186906-A1 | N-((S)-4,4-dimethyl-1-oxo-1-((3aS,6aR)-3-oxo-dihydro-2H-furo[3,2-b]pyrrol-4(5H6H, 6aH)-yl)pentan-2-yl)-4-(4-methylpiperazin-1-yl)benzamide; treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, bone cancer | COL2A1, COL1A1, PTMS | GRM5 1452/4885MIF 1274/4885MAPT 889/4885 |
| US-20100144808-A1 | SUBSTITUTED ISOXAZOLINE OR ENONE OXIME COMPOUND, AND PEST CONTROL AGENT | MLYCD, MT-CO2, TRHDE | GRM5 824/4885MIF 3249/4885MAPT 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.